EPO and chronic kidney disease: Finally, as long as EPO trials in AKI or critical care setting are not showing benefits on mortality and as long as higher doses might cause thromboembolic complications, the end-point of these trials should focus more on patient-reported outcomes as discussed by Drüeke T. regarding ESA use in chronic kidney disease patients [34].